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1154The Identification of Potential
Therapeutic Targets for Cutaneous
Squamous Cell Carcinoma
Angela McHugh1,5, Kenneth Fernandes1,5, Nerime Chinner1, Adel F.M. Ibrahim2, Amit K. Garg2,
Garry Boag1, Lydia A. Hepburn1, Charlotte M. Proby1,3, Irene M. Leigh1,4 and Mark K. Saville1We performed a small interfering RNA screen to identify targets for cutaneous squamous cell carcinoma (cSCC)
therapy in the ubiquitin/ubiquitin-like system. We provide evidence for selective anti-cSCC activity of knock-
down of the E3 ubiquitin ligase MARCH4, the ATPase p97/VCP, the deubiquitinating enzyme USP8, the cullin-
RING ligase (CRL) 4 substrate receptor CDT2/DTL, and components of the anaphase-promoting complex/
cyclosome (APC/C). Specifically attenuating CRL4CDT2 by CDT2 knockdown can be more potent in killing cSCC
cells than targeting CRLs or CRL4s in general by RBX1 or DDB1 depletion. Suppression of the APC/C or forced
APC/C activation by targeting its repressor EMI1 are both potential therapeutic approaches. We observed that
cSCC cells can be selectively killed by small-molecule inhibitors of USP8 (DUBs-IN-3/compound 22c) and the
NEDD8 E1 activating enzyme/CRLs (MLN4924/pevonedistat). A substantial proportion of cSCC cell lines are very
highly MLN4924-sensitive. Pathways that respond to defects in proteostasis are involved in the anti-cSCC ac-
tivity of p97 suppression. Targeting USP8 can reduce the expression of growth factor receptors that participate
in cSCC development. EMI1 and CDT2 depletion can selectively cause DNA re-replication and DNA damage in
cSCC cells.
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There is a need for improved treatment for cutaneous squa-
mous cell carcinoma (cSCC) in high-risk recessive dystrophic
epidermolysis bullosa (RDEB) and immunocompromised
patients, including transplant recipients and in the general
population (Harwood et al., 2016; Mellerio et al., 2016). This
includes better systemically and locally delivered therapy.
The cumulative risk of death from cSCC in patients with
RDEB is 80% by the age of 55 years, and overall, cSCC
causes 25% of skin cancererelated deaths. cSCC, including
multiple primary tumors in high-risk individuals, also results
in considerable morbidity.
The ubiquitin/ubiquitin-like system plays a widespread role
in regulating cellular pathways and processes. It contains
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an oE2 conjugating enzymes, E3 ligases, receptors for ubiquitin/
ubiquitin-like proteins, ATPases, and proteases. Considerable
work has been carried out to target this system for cancer
therapy, and there are a growing number of small-molecule
modulators.
We have shown that proteasome and ubiquitin E1 in-
hibitors have therapeutic potential for cSCC (McHugh et al.,
2018). In this study, we screened using a small interfering
RNA (siRNA) library complementary to more than 1,000
genes to identify additional components of the ubiquitin/
ubiquitin-like system that could be targeted for cSCC ther-
apy. We assessed the cSCC selectivity compared with that of
normal skin cells of knockdown and small-molecule inhibi-
tion of targets identified in the screen. We also initiated
studies to investigate mechanisms of anti-cSCC activity.
RESULTS AND DISCUSSION
siRNA screening for potential therapeutic targets
A cell line derived from a primary RDEB cSCC (SCCRDEB4)
was transfected with pools of four siRNAs targeting 1,186
ubiquitin/ubiquitin-like pathway-linked genes (MacKay et al.,
2014). Cell viability was reduced by >65% by siRNA pools
targeting 66 genes (Supplementary Figure S1). Of these, six
encoded for ubiquitin systemerelated components of the
spliceosome, which we have investigated in detail (Hepburn
et al., 2018). To identify genuine targets, we determined the
effects on viability and death in SCCRDEB4 cells of four in-
dividual siRNAs. Variations in the responses to siRNAs could
arise from differences in their effectiveness in knocking down
the target and its splice variants as well as false-negative or
false-positive off-target effects. At least two siRNAs reduced
cell viability (live cell number) by >60% for 34 genes ands. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Targets in the ubiquitin/
ubiquitin-like system for which at
least two siRNAs substantially
reduced viability. SCCRDEB4 cells
were mock transfected () or
transfected with nontargeting siRNA
(Control), cytotoxic siRNA (Tox), or
four individual siRNAs for each target.
Cell viability (percentage of control
live cell number) and the percentage
of dead cells were determined by real-
time imaging 96 hours after
transfection. Values are the mean 
range of two experiments or  the SD
of at least three experiments. The
cellular roles of targets are indicated.
APC/C, anaphase-promoting
complex/cyclosome; CRL, cullin-
RING ligase; SD, standard deviation;
siRNA, small interfering RNA.
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Targeting the Ubiquitin System in cSCCincreased cell death to >30% for 22 genes (Figure 1). Some
of these genes encoded for proteins that are subunits of the
same complexes, others for proteins that participate in the
same cellular processes. For most of the remaining targets,
only a single siRNA had a robust effect on cell viability and
death (Supplementary Figure S2).Additional target validation
To further investigate the therapeutic potential of suppression
of genes for which multiple individual siRNAs had a
phenotype, we determined the effects of the siRNAs on
viability and death in normal skin cells (fibroblasts and ker-
atinocytes) and cell lines derived from metastasis in an RDEB
(SCCRDEBMet) and a transplant patient (SCCTMet). A cyto-
toxic siRNA was used in each experiment as a control for
transfection efficiency. In addition, we determined the extent
of target protein knockdown in normal and cSCC cells. Theeffects of small-molecule inhibitors on viability and death in
normal skin cells and cSCC cell lines were also evaluated.
MARCH4. MARCH4 is a little-studied transmembrane E3
ubiquitin ligase that is localized to the Golgi apparatus
(Bartee et al., 2004; Bauer et al., 2017; Samji et al., 2014).
Ectopically expressed MARCH4 increases lysosomal degra-
dation of several proteins that promote immune responses,
and its knockdown increases cell surface levels of the scaf-
folding protein tetraspanin CD81 (Bartee et al., 2010).
However, there are likely to be additional MARCH4 sub-
strates (Nathan and Lehner, 2009).
MARCH4 siRNAs had little effect on death in normal skin
cells, whereas two MARCH4 siRNAs caused a reduction in
viability and increased death in cSCC cell lines (Figure 2a).
We were unable to detect MARCH4 protein with available
antibodies (data not shown). However, we confirmed that
MARCH4 mRNA levels were reduced in normal humanwww.jidonline.org 1155
Figure 2. MARCH4 and p97 knockdown selectively kills cSCC cells. Normal skin cells (NHF and NHK) and cSCC lines (SCCRDEB4, SCCRDEBMet, and
SCCTMet) were mock transfected () or transfected with siRNAs as indicated. (a, c) Cell viability and the percentage of dead cells were determined by real-time
imaging following transfection with four siRNAs targeting (a) MARCH4 or (c) p97: mean SD of at least three experiments (NHK, NHF, and SCCRDEB4 cells) or
the range of two experiments (SCCRDEBMet and SCCTMet cells). (b)MARCH4mRNA knockdown: mean range of two experiments. (d) p97 protein knockdown.
(e) Co-transfection of control or p97(D) siRNAs with siRNAs targeting genes involved in responding to defects in proteostasis (two siRNAs per target): mean
percentage of cell death in p97(D) and control siRNA-transfected cells  SD of four experiments. cSCC, cutaneous squamous cell carcinoma; NHF, normal human
fibroblast; NHK, normal human keratinocyte; SD, standard deviation; siRNA, small interfering RNA; Tox, cytotoxic small interfering RNA.
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Targeting the Ubiquitin System in cSCCkeratinocytes by MARCH4 siRNAs and that in SCCRDEB4
cells, the siRNAs most potent in killing cSCC cells caused the
largest reduction in MARCH4 mRNA levels (Figure 2b).
p97/VCP. p97 is an ATPase that unfolds ubiquitinated
proteins and extracts them from membranes, cellular struc-
tures, and complexes (van den Boom and Meyer, 2018; Ye
et al., 2017). Through this, p97 can facilitate substrate
degradation by the proteasome, and it can also regulate
substrate activity, complex assembly, and membrane fusion.
p97 participates in a wide range of cellular processes. It
maintains protein homeostasis (proteostasis) by promoting
the proteasomal degradation of misfolded proteins associated
with the endoplasmic reticulum, ribosomes, and mitochon-
dria. It also regulates lysosomes and autophagosome matu-
ration. Other roles of p97 include the control of key proteins
involved in signal transduction, DNA replication, and DNA
repair. Distinct p97 complexes are involved in particular
cellular processes; p97 associates with numerous adaptors
and cofactors that recruit substrates and participate in sub-
strate processing (Stach and Freemont, 2017; Ye et al., 2017).
p97 siRNAs killed cSCC lines but not normal skin cells,
whereas p97 was depleted in both normal human kerati-
nocytes and SCCRDEB4 cells (Figure 2c and d). We inves-
tigated whether p97 knockdowneinduced death was
dependent on pathways that sense defects in proteostasis.
Death due to depletion of p97 was attenuated by suppres-
sion of proteins involved in responses to the accumulation
of unfolded proteins in the endoplasmic reticulum (ATF6,
IRE1a/JNK1, and PKR/eiF2a) and to amino acid depletion
(GCN2/eiF2a) (Figure 2e) (McConkey, 2017; Parzych
et al., 2015). cSCCs have frequent gene copy number
changes, and UV-induced cSCCs in particular have
extremely high gene mutation rates (Cho et al., 2018; Inman
et al., 2018; South et al., 2014). These alterations can confer
greater dependency on mechanisms of proteostasis by
causing imbalanced protein production, which can generate
free components of complexes that cannot fold appropri-
ately, and through the generation of proteins that are mis-
folded because of mutations (Deshaies, 2014; Vekaria et al.,
2016). Consistent with greater basal proteotoxic stress, there
is an increase in the expression of proteasome subunits and
Ser51 phosphorylated eiF2a in cSCC cell lines compared
with normal skin cells (McHugh et al., 2018).
Numerous small-molecule p97 inhibitors have been
developed (Chapman et al., 2015; Vekaria et al., 2016; Ye
et al., 2017). The well-characterized p97 inhibitors DBeQ
and NMS-873 were at best modestly selective for effects on
viability and death in cSCC lines compared with normal
skin cells, and the sensitivity of the most responsive cSCC
lines was around average for tumor-derived cells
(Supplementary Figure S3) (Magnaghi et al., 2013; Parzych
et al., 2015). It is possible that the differences in the cSCC
selectivity of these inhibitors and p97 knockdown are due
to divergent effects on the spectrum of p97-regulated
pathways. For example, the effects of p97 knockdown
could be influenced by competition of binding partners for
residual p97. The potency of p97 inhibitors can be differ-
entially affected by p97-interacting proteins, potentially
resulting in preferential effects of inhibitors on particularcomplexes (Gui et al., 2016). It would be of interest to
compare additional p97 inhibitors to determine if greater
cSCC selectivity can be achieved.
USP8. Sorting of endocytosed, activated cell surface re-
ceptors for lysosomal degradation or recycling to the plasma
membrane is mediated by endosomal sorting complexes
required for transport (ESCRT). Ubiquitination of receptors
promotes ESCRT-mediated lysosomal trafficking. USP8/
UBPY-mediated deubiquitination of some ESCRT-associated
receptors can facilitate their recycling, and USP8 also regu-
lates endocytic sorting by stabilizing ESCRT-0 proteins HGS,
STAM, and STAM2 (D’Arcy et al., 2015; Niendorf et al.,
2007; Wright et al., 2011).
USP8 siRNAs reduced viability and increased death in
cSCC lines but had little effect in normal skin cells
(Figure 3a). The anti-cSCC potency of these siRNAs reflected
their ability to reduce USP8 protein levels (Figure 3b). siRNA
USP8(A) depleted USP8 to the greatest extent, and this was
associated with reduced expression of growth factor re-
ceptors MET, EGFR, and ERBB2, along with HGS and STAM2.
siRNAs USP8(B) and (C) reduced expression of MET and
STAM2. This is consistent with a role of USP8 in protecting
these proteins from degradation.
Small-molecule USP8 inhibitors have been identified
including DUBs-IN-3/compound 22c (Colombo et al., 2010;
D’Arcy et al., 2015). DUBs-IN-3 killed cSCC lines at lower
concentrations than normal skin cells (Figure 3e). Reduced
MET, EGFR, and STAM2 expression was consistent with
attenuation of USP8 at DUBs-IN-3 concentrations that
selectively increased death in cSCC cells (Figure 3d). We
observed that directly targeting MET, EGFR, or ERBB2 was
sufficient to impact cSCC cell viability (Figure 3c). MET and
EGFR/ERBB2 signaling pathways can contribute to driving
cSCC development, and a subset of cSCCs respond to EGFR
inhibitors (Cataisson et al., 2016; Harwood et al., 2016;
Mellerio et al., 2016). Suppression of USP8 could provide a
means to simultaneously interfere with multiple therapeuti-
cally relevant receptors, which could overcome resistance
because of receptor redundancy or cross-talk.
Anaphase-promoting complex/cyclosome (APC/C). The
APC/C is a multisubunit E3 ligase that coordinates transitions
through the cell cycle by targeting key proteins for protea-
somal degradation (Alfieri et al., 2017; Zhou et al., 2016).
CDC20 and CDH1/FZR1 are coactivators that associate with
the core APC/C complex at different stages of the cell cycle
and recruit overlapping but distinct sets of substrates for
ubiquitination. APC/CCDC20 drives progression through
mitosis (Kapanidou et al., 2017). APC/CCDC20 is inhibited by
the spindle assembly checkpoint until chromosomes are
properly attached to spindle microtubules. Following transi-
tion through the spindle assembly checkpoint, APC/CCDC20
promotes the degradation of securin and cyclin B, allowing
chromatid segregation and mitotic exit. In late mitosis and
G1, APC/CCDH1 participates in promoting licensing of DNA
for replication by allowing the recruitment of the pre-
replicative complex to replication origins (Hernández-
Carralero et al., 2018; Moreno and Gambus, 2015). This in-
volves APC/CCDH1-mediated degradation of geminin, whichwww.jidonline.org 1157
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Figure 3. Suppression of USP8 has selective anti-cSCC activity. (a) Cell viability and the percentage of dead cells were determined by real-time imaging 96
hours after transfection with USP8 siRNAs: mean  SD of at least three experiments (NHK, NHF, and SCCRDEB4 cells) or  the range of two experiments
(SCCRDEBMet and SCCTMet cells). (b) Protein expression was analyzed by western blotting 48 hours after transfection with USP8 siRNAs. (c) Cell viability and
the percentage of dead cells 96 hours after transfection with two siRNAs targeting growth factor receptors: mean  SD of four experiments. (d) Western
blot analysis of SCCRDEB4 cells treated with the USP8 inhibitor DUBs-IN-3 for 24 hours. (e) Cell viability and the percentage of dead cells 72 hours after
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Targeting the Ubiquitin System in cSCCis an inhibitor of the key replication licensing factor CDT1,
and suppression of cyclin A and B CDK complexes, which
inhibit replication licensing. The attenuation of cyclin/CDKs
also contributes to APC/CCDH1-mediated blockade of cell-
cycle progression. In late G1, S, and G2 phase, cells’ APC/
CCDH1 activity is inhibited in part by E2F-dependent induc-
tion of the APC/C-binding protein EMI1. This prevents further
rounds of DNA replication licensing and permits entry into S
phase (Abbas and Dutta, 2017; Cappell et al., 2016; Reimann
et al., 2001). APC/CCDH1 thus participates in allowing
licensing to occur only before the onset of DNA replication,
which contributes to ensuring that the genome is just dupli-
cated once per cell cycle.
siRNA pools targeting 10 of the 14 core subunits of the
APC/C substantially reduced viability in our primary screen,
and multiple individual APC/C core subunit siRNAs killed
SCCRDEB4 cells (Supplementary Figure S1 and Figure 4a).
There was little effect on viability or death of targeting core
APC/C subunits in normal skin cells, but effects on
SCCRDEBMet and SCCTMet cells were also generally modest
(Figure 4a). Interfering with coactivators CDC20 and CDH1
provides a means to specifically suppress different APC/C
functions. Two of the CDC20 siRNAs selectively killed cSCC
cell lines, whereas they robustly reduced CDC20 protein
expression in both normal skin cells and SCCRDEB4 cells
(Figure 4b). siRNA CDC20(D) was the least effective in
depleting CDC20 and had no effect on viability or death.
Three CDH1 siRNAs depleted CDH1 without causing a high
level of death in cSCC cells (Figure 4a and c). These data
suggest that CDC20 rather than CDH1 has potential as a
therapeutic target for cSCC.
CDC20 is essential for mitosis, but a high level of sup-
pression is required to block cell-cycle progression in normal
cells and in many tumor cells (Baumgarten et al., 2009;
Crawford et al., 2016; Jin et al., 2010; Kidokoro et al.,
2008; Li et al., 2014, Li et al., 2007; Taniguchi et al., 2008;
Wirth et al., 2004; Zhang et al., 2014). The robust effects of
targeting APC/C core subunits and CDC20 in SCCRDEB4
cells likely reflects sensitivity to partial suppression of APC/C.
A need to maintain elevated levels of CDC20 for survival may
contribute to cell death induced by CDC20 depletion in
SCCRDEB4 and SCCRDEBMet cells (Supplementary
Figure S4). Small-molecule antagonists of CDC20/CDH1
(TAME) and CDC20 (apcin) are at an early stage of devel-
opment (Kapanidou et al., 2017; Sackton et al., 2014; Wang
et al., 2015; Zeng et al., 2010). Antimitotic agents, including
compounds that interfere with microtubule dynamics and
Aurora A and PLK-1 inhibitors, act in part by attenuating
APC/CCDC20 by activating the spindle assembly checkpoint
(Olziersky and Labidi-Galy, 2017). Previous studies indicate
PLK-1 is a potential target for cSCC therapy (Watt et al.,
2011). Direct APC/CCDC20 suppression may be a better
therapeutic approach than spindle assembly checkpoint
activation because directly targeting APC/CCDC20 attenuates
premature exit from mitosis (Huang et al., 2009).
We also observed that siRNAs targeting the APC/C
repressor EMI1 killed cSCC lines with no effect on death in=
initiation of DUBs-IN-3 treatment: mean  range of two experiments. cSCC, cutan
human keratinocyte; SD, standard deviation; siRNA, small interfering RNA; Tox,normal skin cells (Figure 4a). This included SCCRDEBMet
and SCCTMet cells, which were relatively resistant to sup-
pression of APC/C. The anti-cSCC potency of the siRNAs was
consistent with the extent of EMI1 knockdown (Figure 4d).
We investigated the role of DNA re-replication in EMI1
knockdown-dependent death. EMI1 depletion caused a
greater increase in DNA re-replication (greater than G2/M
DNA content) in cSCC cells than in normal human fibroblasts
along with a tumor celleselective increase in the DNA
damage marker gH2AX (Figure 4d and e and Supplementary
Figure S5a). Furthermore, death induced by EMI1 depletion
was dependent on the DNA replication licensing factor
CDT1 (Figure 4f). This is in line with previous studies in other
cell types showing that reduced viability following EMI1
suppression can be caused by APC/CCDH1-dependent DNA
re-replication leading to DNA damage (Machida and Dutta,
2007; Neelsen et al., 2013; Shimizu et al., 2013;
Verschuren et al., 2007).
High expression of replication licensing factors increases
susceptibility to re-replication (Benamar et al., 2016; Muñoz
et al., 2017; Vaziri et al., 2003). Elevated expression of
replicating licensing proteins including CDT1 compared with
normal skin cells consequently provides a mechanism that
could contribute to increased re-replication in cSCC cells on
targeting components of the protective machinery including
EMI1 (Supplementary Figure S4). This is supported by the
observation that depletion of CDT1 diminished EMI1
knockdowneinduced death (Figure 4f). EMI1 increases
expression of the CDT1 repressor geminin by attenuating
APC/CCDH1-mediated geminin degradation. In normal cells,
geminin accumulates inactive CDT1 in preparation for the
next round of replication licensing (Ballabeni et al., 2004;
Ballabeni et al., 2013). EMI1 protein expression was
strongly upregulated in cSCC cell lines, which could prime
cSCC cells for re-replication by contributing to the accumu-
lation of CDT1 (Supplementary Figure S4). Consistent with
this, we observed that EMI1 and CDT1 protein expression
was frequently co-upregulated in cSCC cell lines, and EMI1
knockdown reduced both geminin and CDT1 protein levels
(Supplementary Figure S4 and Figure 4d).
Cullin-RING Ligase (CRL) 4CDT2. CRLs are a very large
family of multisubunit E3 ubiquitin ligases containing 1 of 8
cullin scaffolds (Bulatov and Ciulli, 2015; Jang et al., 2018).
CRL4s are composed of cullin4(A/B), DDB1 adaptor, RBX1
E2-binding RING finger, and one of many substrate-recruiting
receptors (Hannah and Zhou, 2015). RBX1 is a component of
multiple CRLs, cullin4 and DDB1 are present in all CRL4s,
and the receptors determine substrate specificity and conse-
quently the cellular roles of CRL4 complexes. siRNAs tar-
geting DDB1, RBX1, and the CRL4 substrate receptors
DCAF1/VPRBP and CDT2/DTL reduced viability in cSCC cell
lines but had only a modest effect in normal skin cells
(Figure 5a). This indicates targeting CRL4s, in particular
CRL4DCAF1 or CRL4CDT2, can have selective anti-cSCC ac-
tivity. In support of this, suppression of CRL4s protects against
UV-induced skin cancer in mice (Hannah and Zhou, 2013).eous squamous cell carcinoma; NHF, normal human fibroblast; NHK, normal
cytotoxic small interfering RNA.
www.jidonline.org 1159
b
NHK SCCRDEB4
CDC20
tubulin
siRNA -
C
on
tr
ol
C
D
C
20
(A
)
C
D
C
20
(B
)
C
D
C
20
(C
)
C
D
C
20
(D
) -
C
on
tr
ol
C
D
C
20
(A
)
C
D
C
20
(B
)
C
D
C
20
(C
)
C
D
C
20
(D
)
c
SCCRDEB4
CDH1
tubulin
siRNA -
C
on
tr
ol
C
D
H
1(
A
)
C
D
H
1(
B
)
C
D
H
1(
C
)
C
D
H
1(
D
)
e
0
siRNA
-
C
on
tr
ol
E
M
I1
(A
)
E
M
I1
(C
) -
C
on
tr
ol
E
M
I1
(A
)
E
M
I1
(C
)
5
20
25
10
15
30
NHF SCCRDEB4
%
 R
e-
R
ep
lic
at
io
n
f
0
siRNA
-
C
on
tr
ol
Control
C
D
T
1(
A
)
C
D
T
1(
B
)
20
80
100
40
60
120
SCCRDEB4
C
el
l D
ea
th
-
C
on
tr
ol
EMI1(C)
C
D
T
1(
A
)
C
D
T
1(
B
)
d
NHF
*
SCCRDEB4
EMI1
geminin
CDT1
γH2AX
H2AX
actin
siRNA -
C
on
tr
ol
E
M
I1
(A
)
E
M
I1
(B
)
E
M
I1
(C
)
E
M
I1
(D
) -
C
on
tr
ol
E
M
I1
(A
)
E
M
I1
(B
)
E
M
I1
(C
)
E
M
I1
(D
)
*
a
0
-
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1
20
siRNA
80
100
40
60
120
NHF NHK SCCRDEB4 SCCRDEBMet SCCTMet
%
 C
el
l D
ea
th
0
-
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1 -
C
on
tr
ol
T
ox
A
N
A
P
C
2
A
N
A
P
C
4
A
N
A
P
C
5
A
N
A
P
C
11
C
D
C
23
C
D
C
26
C
D
C
27
C
D
C
20
C
D
H
1
E
M
I1
20
siRNA
80
100
120
40
60
140
NHF NHK SCCRDEB4 SCCRDEBMet SCCTMet
%
 L
iv
e 
C
el
l N
um
be
r
Core subunit
Coactivator
Repressor
Figure 4. APC/C suppression and derepression have potential for cSCC therapy. (a) Cells were transfected with four siRNAs per target. Cell viability and the
percentage of dead cells were assessed 96 hours after transfection by real-time imaging: mean  SD of at least three experiments (CDC20, CDH1, and EMI1 in
NHK, NHF, and SCCRDEB4 cells) or  range of two experiments. (bed) Protein expression analyzed 48 hours after transfection with siRNAs targeting (b)
CDC20, (c) CDH1, and (d) EMI1. Geminin (upper band *) and CDT1 expression was reduced by EMI1 knockdown. (e) The percentage of cells in which DNA
was re-replicated 72 hours after siRNA transfection: mean  range of two experiments. (f) Cell death 72 hours after siRNA co-transfection: percentage of that in
EMI1(C) and control siRNA-transfected cells: mean  SD of three experiments. APC/C, anaphase-promoting complex/cyclosome; cSCC, cutaneous squamous
cell carcinoma; NHF, normal human fibroblast; NHK, normal human keratinocyte; SD, standard deviation; siRNA, small interfering RNA; Tox, cytotoxic small
interfering RNA.
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Targeting the Ubiquitin System in cSCCCDT2 knockdown could cause more death in cSCC cells
than targeting RBX1 or DDB1 (Figure 5a and b). RBX1/DDB1
depletion may elicit prosurvival responses through attenua-
tion of CRLs in addition to CRL4CDT2. Similar to EMI1,
CRL4CDT2 is involved in protecting against DNA re-
replication (Abbas and Dutta, 2011; Abbas and Dutta,
2017; Moreno and Gambus, 2015). During S-phase and
DNA repair, CRL4CDT2 promotes the DNA
replicationecoupled proteasomal degradation of PCNAe-
bound proteins involved in promoting replication licensing
including CDT1, SET8, and p21 (Havens and Walter, 2011;
Hernández-Carralero et al., 2018; Scrima et al., 2011).
CDT2 was efficiently knocked down in both normal human
fibroblasts and cSCC cells (Figure 5c). This resulted in the
accumulation of the CRL4CDT2 substrates SET8 and p21 but
not CDT1. Failure to accumulate CDT1 is consistent with
previous observations in other cell types and can result from
context-dependent CDT1 regulatory mechanisms (Benamar
et al., 2016). We observed that CDT2 depletion caused
cSCC-selective DNA re-replication and DNA damage and
that CDT2 knockdowneinduced death in cSCC cells was
SET8-dependent (Figure 5cee and Supplementary
Figure S5a). This is consistent with a key role of re-
replication in the antitumor activity of CDT2 suppression
(Benamar et al., 2016; Olivero et al., 2014).
There are no direct small-molecule inhibitors of CDT2.
However, MLN4924/pevonedistat, an inhibitor of the
NEDD8-activating enzyme, attenuates CRLs by blocking
their NEDDylation (Abidi and Xirodimas, 2015). DNA re-
replication due at least in part to CRL4CDT2 suppression can
make a substantial contribution to the antitumor activity of
this inhibitor, although interference with other pathways is
also involved (Abbas and Dutta, 2017; Benamar et al., 2016;
Zhou et al., 2018). In cSCC cells, MLN4924 caused DNA re-
replication and altered expression of proteins involved in
promoting replication licensing, although the pattern of
changes was different from that caused by CDT2 knockdown
(Figures 6a and 5c and Supplementary Figure S5b). It also
increased gH2AX, indicative of DNA damage. Viability was
reduced at low MLN4924 concentrations in SCCRDEB4,
SCCRDEBMet, SCCT, and SCCTMet cells treated continu-
ously for 72 hours (Figure 6b). Comparison with the GDSC
Database (Release 8.0) indicates these cSCC lines are in the
very highly MLN4924/pevonedistat-sensitive subset of
cancer-derived cells (Yang et al., 2013). Death in SCCIC1,
SCCT, SCCTMet, and SCCT8 cells was more sensitive than in
normal skin cells to continuous MLN4924 treatment. In
addition, SCCRDEB4, SCCT, and SCCTMet cells were selec-
tively killed by an 8-hour pulse of MLN4924, which mimics
systemically delivered inhibitor pharmacokinetics (Swords
et al., 2015). Clonogenic assays confirmed these differences
in sensitivity to a pulse of MLN4924 (Figure 6c). At low
concentrations, MLN4924 promoted growth in SCCRDEB2
and SCCIC1 cells. Enhanced cell growth has been observed
previously but is unusual and requires additional investiga-
tion (McMillin et al., 2012). p21 expression was high in three
of the cSCC lines most insensitive to a pulse of MLN4924
(SCCIC1, SCCRDEB2, and SCCRDEB3) and p21 knockdown
enhanced MLN4924-induced cell death in SCCRDEB2 cells(Supplementary Figures S4 and S6). This is consistent with
previous reports that p21 can be protective against MLN4924
(Blank et al., 2013; Lin et al., 2010). Elevated basal p21 may
consequently be a marker for resistance of cSCC cells to
MLN4924. Wild-type p53 can protect against MLN4924 in
part through p21 induction; however, p53 is mutated in all
cSCC lines (Lin et al., 2010; Malhab et al., 2016). Given the
particular efficacy of CDT2 knockdown in killing cSCC cells,
the differences in modulation of CRL4CDT2 substrates
observed with CDT2 depletion and MLN4924, and the ef-
fects of MLN4924 on multiple pathways, it would be of in-
terest to develop CDT2-specific inhibitors.
MATERIALS AND METHODS
Cell culture
Cells were maintained and plated as previously described (McHugh
et al., 2018). SCCRDEBMet (SCCRDEB70) and RDEBK cells were
provided by Andrew P. South (Thomas Jefferson University), Jemima
E. Mellerio (King’s College London), and Julio C. Salas-Alanı́s
(DEBRA Mexico). SCCT (previously published as MET1), SCCTMet
(previously published as MET4), SCCIC1, and SCCIC1Met cell lines
are derived from paired primary tumors and metastases (Hassan
et al., 2019; Proby et al., 2000; Watt et al., 2011).
siRNA transfection
Dharmacon ON-TARGETplus modified siRNAs (Thermo Fisher Sci-
entific, Waltham, MA) were used in this study to minimize off-target
effects. Reverse transfection with synthetic siRNA duplexes (10 nM)
was performed using Invitrogen Lipofectamine RNAiMAX (Thermo
Fisher Scientific). The library used for the primary screen containing
pools of four siRNAs per gene was detailed previously (MacKay
et al., 2014). Additional siRNAs are listed in Supplementary
Figure S7a.
Inhibitor treatment
Inhibitors used in this work were DBeQ and NMS-873 (Sell-
eckchem, Houston, TX), DUBs-IN-3/compound 22c (Medchemex-
press, South Brunswick Township, NJ), and MLN4924 (Boston
Biochem, Cambridge, MA).
Cell viability assays
For the primary screen, viability was measured by ATPase assay 96
hours after siRNA transfection (MacKay et al., 2014). Where indi-
cated, live cell number and cell death were analyzed 96 hours after
siRNA transfection or 72 hours after the initiation of inhibitor
treatment using an Incucyte ZOOM real-time imager (Essen
BioScience Ltd, Welwyn Garden City, United Kingdom) and the
CellTox Green Cytotoxicity Assay (Promega, Madison, WI). For
clonogenic assays, MLN4924 was added for 8 hours, and cells were
maintained in drug-free medium for up to 2 weeks. Colonies were
fixed in 10% methanol and 10% acetic acid and stained with crystal
violet.
DNA re-replication
To assess re-replication (>G2/M DNA content), fixed DAPI-stained
samples were analyzed for DNA content using a NucleoCounter
NC-3000 cell counter (ChemoMetec, Allerod, Denmark) according
to the manufacturer’s instructions.
Western blotting
Primary antibodies are listed in Supplementary Figure S7b. Cell
extracts were made by lysis into SDS electrophoresis sample buffer.www.jidonline.org 1161
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Figure 5. CRL4CDT2 is a potential therapeutic target for cSCC. (a) Cells were transfected with four siRNAs targeting the CRL4 adaptor DDB1 and substrate
receptors DCAF1 and CDT2 and the CRL/CRL4 RING finger protein RBX1. Viability and the percentage of dead cells were assessed by real-time imaging after 96
hours: mean  range of two experiments. (b, c) Protein expression was analyzed after 48 hours with four siRNAs targeting (b) DDB1, RBX1, DCAF1, and CDT2
in SCCRDEB4 cells and (c) CDT2 in NHF and SCCRDEB4 cells. (d) The percentage of cells in which DNA was re-replicated 72 hours after siRNA transfection:
mean  range of two experiments. (e) Viability and death were assessed by real-time imaging 96 hours after siRNA co-transfection: percentage of cell death in
A McHugh et al.
Targeting the Ubiquitin System in cSCC
Journal of Investigative Dermatology (2020), Volume 1401162
b
[MLN4924] (μM)
0
0 0.01 0.1 1 10
50
200
250
100
150
300
Continuous
%
 L
iv
e 
C
el
l N
um
be
r
[MLN4924] (μM)
0
0 0.1 1 10
40
80
120
160
Pulse
%
 L
iv
e 
C
el
l N
um
be
r
[MLN4924] (μM)
0
0 0.01 0.1 1 10
60
20
40
80
Continuous
%
 C
el
l D
ea
th
[MLN4924] (μM)
0
0 0.1 1 10
20
40
60
80
Pulse
%
 C
el
l D
ea
th
[MLN4924] (μM)
0
0 0.01 0.1 1 10
100
50
150
200
250
Continuous
%
 L
iv
e 
C
el
l N
um
be
r
[MLN4924] (μM)
0
0 0.1 1 10
100
50
150
200
250
Pulse
%
 L
iv
e 
C
el
l N
um
be
r
[MLN4924] (μM)
0
0 0.01 0.1 1 10
40
20
60
80
100
Continuous
%
 C
el
l D
ea
th
[MLN4924] (μM)
0
0 0.1 1 10
20
40
60
80
Pulse
%
 C
el
l D
ea
th
c
SCCRDEB4
SCCRDEB2
SCCT
NHF
SCCIC1
SCCTMet
SCCIC1Met
SCCRDEB3
a
8 Hours
SCCRDEB4
[MLN4924] (μM)
24 Hours
CDT2
CDT1
SET8
p21
γH2AX
H2AX
actin
0 1
0.
3
0.
1
0.
01 10 0 10.
3
0.
1
0.
01 10
SCCTMet
NHK
SCCT
NHF
SCCT8
SCCIC1 SCCIC1MetSCCRDEB3RDEBK SCCRDEB2
SCCRDEB4 SCCRDEBMet
Figure 6. A subset of cSCC lines are more sensitive than normal skin cells to death induced by MLN4924. (a) SCCRDEB4 cells were incubated with the NEDD8
E1 activating enzyme/CRL inhibitor MLN4924 for 8 and 24 hours. Protein expression was analyzed by western blotting. (b) Normal skin cells (NHF, NHK, and
RDEBK) or cSCC lines were continuously incubated with MLN4924 for 72 hours (Continuous) or treated with MLN4924 for 8 hours and then maintained in
drug-free medium for a further 64 hours (Pulse). Cell viability and death were assessed by real-time imaging: mean  SD of three experiments. (c) Cells were
incubated with the indicted concentration of MLN4924 (mM) for 8 hours (comparable to the pulse) and then maintained in drug-free medium to allow colony
formation. cSCC, cutaneous squamous cell carcinoma; CRL, cullin-RING ligase; NHF, normal human fibroblast; NHK, normal human keratinocyte; SD,
standard deviation.
A McHugh et al.
Targeting the Ubiquitin System in cSCCWestern blotting was carried out as previously described (Dayal
et al., 2009).Real-time PCR
RNA was extracted using RNeasy columns and real-time PCR were
performed as previously described (Dayal et al., 2009) using
MARCH4 probe/primer set Hs00863129_m1 (Thermo Fisher Scien-
tific). TBP was used for normalization.=
CDT2(B) and control siRNA transfected cells: mean  SD of three experiments.
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Supplementary Figure S1. Sixty-six siRNA pools in the ubiquitin/ubiquitin-like pathway library reduced viability by more than 65%. SCCRDEB4 cells were
transfected with a pool of four nontargeting siRNAs (Control) or pools of four siRNAs complementary to 1,186 ubiquitin/ubiquitin-like systemerelated genes.
Cell viability was determined 96 hours after transfection by ATPase assay. The average Z-prime for the screen was 0.82. Values are the mean percentage of
control  SD of three determinations. The effects of four individual siRNAs are indicated (Pool deconvolution). siRNA, small interfering RNA.
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Supplementary Figure S2. Targets from the primary screen for which multiple siRNAs did not cause a substantial reduction in viability. SCCRDEB4 cells were
transfected with four individual siRNAs per target gene and cell viability (percentage of control live cell number) and the percentage of dead cells were
assayed by real-time imaging. Values are the mean  range of two determinations. For many of these targets, only one siRNA had a substantial effect on viability
and death. Although it remains possible this is due to greater efficacy of target knockdown by the siRNA with the strongest phenotype, it could also result from
off-target effects. siRNA, small interfering RNA; Tox, cytotoxic small interfering RNA.
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Supplementary Figure S3. The p97
inhibitors DBeQ and NMS-873 do not
display a high level of selectivity for
cSCC cells. Normal skin cells (NHF
and NHK) and cSCC cell lines derived
from RDEB (SCCRDEB),
immunocompetent (SCCIC), and
immunocompromised transplant
(SCCT) patients were treated for 72
hours with p97 inhibitors. Cell
viability (percentage of control live
cell number) and the percentage of
dead cells were assayed by real-time
imaging. cSCC, cutaneous squamous
cell carcinoma; NHF, normal human
fibroblast; NHK, normal human
keratinocyte; RDEB, recessive
dystrophic epidermolysis bullosa.
Supplementary Figure S4. The APC/C coactivators CDH1 and CDC20, the
APC/C repressor EMI1, and proteins that promote DNA replication licensing
are frequently upregulated in cSCC lines. Protein expression was analyzed by
western blotting in normal skin cells (NHF, NHK, and RDEBK) and a panel of
lines derived from primary and metastatic cSCCs in RDEB (SCCRDEB),
immunocompetent (SCCIC), and transplant (SCCT) patients. NHF1 and 2 and
NHK1 and 2 were from different donors. APC/C, anaphase-promoting
complex/cyclosome; cSCC, cutaneous squamous cell carcinoma; NHF,
normal human fibroblast; NHK, normal human keratinocyte; RDEB, recessive
dystrophic epidermolysis bullosa.
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Supplementary Figure S5a. EMI1 and CDT2 knockdown cause DNA re-replication in cSCC cells. The DNA content of NHF and SCCRDEB4 cells was
analyzed 72 hours after transfection with the indicated siRNA. The percentage of cells that underwent re-replication (>G2/M DNA content) is shown.
cSCC, cutaneous squamous cell carcinoma; NHF, normal human fibroblast; siRNA, small interfering RNA.
Supplementary Figure S5b. MLN4924 promotes DNA re-replication in
cSCC cells. The DNA content of NHF and SCCRDEB4 cells was analyzed 48
hours after treatment with carrier (0) or 1mM MLN4924. The percentage of
cells with >G2/M DNA content is indicated. cSCC, cutaneous squamous cell
carcinoma; NHF, normal human fibroblast; siRNA, small interfering RNA.
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Supplementary Figure S7. Materials
used in this study. (a) siRNAs. (b)
Primary antibodies. siRNA, small
interfering RNA.
Supplementary Figure S6. p21
knockdown partially overcomes
resistance to MLN4924. SCCRDEB2
cells that are relatively insensitive to
MLN4924 were transfected with p21
siRNAs. (a) p21 protein knockdown
assessed by western blotting 48 hours
after transfection. (b) 48 hours after
transfection SCCRDEB2 cells were
exposed to an 8-hour pulse of
MLN4924. Cell death was determined
by real-time imaging 72 hours after
initiating treatment with the inhibitor.
p21 knockdown increased the level of
cell death caused by an 8-hour pulse
of MLN4924. cSCC, cutaneous
squamous cell carcinoma; siRNA,
small interfering RNA.
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